Dermatol. praxi. 2023;17(4):220-223 | DOI: 10.36290/der.2023.039

Bimekizumab in the treatment of psoriasis and psoriatic arthritis

MUDr. Jan Šternberský, Ph.D., MUDr. Martin Tichý, Ph.D.

Klinika chorob kožních a pohlavních, Lékařská fakulta, Univerzita Palackého v Olomouci

Klinika chorob kožních a pohlavních, Fakultní nemocnice Olomouc

The most common comorbidity associated with psoriasis is psoriatic arthritis (PsA). It can significantly impair patients' quality of life and, if not adequately treated, can lead to irreversible, mutilating changes in the joints. Early diagnosis and treatment of PsA is therefore essential for the further development of the disease. Early stages of PsA can often be detected by a dermatologist using a simple "PEST" questionnaire. The final diagnosis of joint involvement and subsequent treatment is then established in cooperation with a rheumatologist. When confirming PsA, we choose a therapy for which, according to the available data, we can assume a high degree of effectiveness in suppressing both psoriasis and PsA activity. From this point of view, the most effective preparations include the IL17 inhibitors ixekizumab, secukinumab and bimekizumab. Bimekizumab is a humanized antibody that selectively binds with high affinity to the cytokines IL-17A, IL-17F and IL-17AF and achieves high efficiency with its dual mechanism of action. It is the most recently registered IL17 inhibitor for the treatment of severe forms of psoriasis and PsA, in the indication of PsA it does not yet have reimbursement from health insurance. We demonstrate the excellent effect of bimekizumab both on the skin manifestations of psoriasis and on the manifestations of PsA in the case report of a 30-year-old patient with arthropathic psoriasis.

Keywords: psoriasis, psoriatic arthritis, bimekizumab, interleukin 17A, interleukin 17F.

Accepted: November 15, 2023; Published: November 21, 2023  Show citation